Zeo ScientifiX, Inc.
No SEC Form 4 filings for $ZEOX in the last 30 days.
See all $ZEOX insider activity →Pluri Inc. (PLUR) and ZEO ScientifiX (ZEOX) have partnered to expand their U.S. manufacturing and commercial platform for regenerative medicine. The deal combines Pluri's cell technology and clinical experience with ZEO's biologics manufacturing and sales network. Pluri will own 50% of ZEO post-closing, with the transaction expected to close in Q4 2026.
Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerativ
Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001557376 0001557376 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning ZEOX (Zeo ScientifiX, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent ZEOX coverage spans corporate actions, mergers & acquisitions and earnings.
Positive catalyst as ZEO gains access to Pluri's technology and product pipeline, enhancing its growth outlook.
The expansion could increase revenue opportunities in two new states but the impact is uncertain for the near term.
This is a primary-source filing that signals newly disclosed operating and financial results, but the scraped text provides no numeric details.
Option awards (some fully vested, some milestone-vesting) at a fixed $1.67 strike can affect near-term dilution expectations and insider/board alignment optics.
AlphAI scores every news story that mentions ZEOX with an AI model for sentiment and relevance, and aggregates insider trades from Zeo ScientifiX, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pluri Inc. (PLUR) and ZEO ScientifiX (ZEOX) have partnered to expand their U.S. manufacturing and commercial platform for regenerative medicine. The deal combines Pluri's cell technology and clinical experience with ZEO's biologics manufacturing and sales network. Pluri will own 50% of ZEO post-closing, with the transaction expected to close in Q4 2026.
3 min readZeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerativ
2 min readZeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001557376 0001557376 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl
3 min readZeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001557376 0001557376 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl
2 min read
